The prophylactic use of low-dose amphotericin B in bone marrow transplant patients

purpose: To evaluate the efficacy of prophylactic low-dose amphotericin B (0.1 mg/kg per day) (LDA) in preventing fungal infections in patients who have had a bone marrow transplant (BMT). materials and methods: Double-blind, randomized, controlled trial in which patients undergoing bone marrow transplantation received intravenous LDA or similar-appearing placebo from the onset of neutropenia until the absolute neutrophil count remained >0.5 × 10 9/L, or until high-dose amphotericin B was initiated. Weekly surveillance cultures were obtained from all patients. results: Five of 18 patients (28%) randomized to placebo developed documented systemic fungal infections within the first 30 days after transplantation, compared to none of 17 patients who received LDA ( P = 0.045). LDA recipients received fewer days of high-dose amphotericin B ( P = 0.04) and fewer days of antibiotics ( P = 0.008). There were trends towards fewer days of hospitalization ( P = 0.14) and improved survival ( P = 0.08); these differences were statistically significant among recipients of allogeneic BMT. No adverse effects occurred with LDA therapy. conclusions: LDA appears to be safe and to reduce early systemic fungal infections in BMT recipients. Improved survival was observed among LDA recipients, but this was not directly attributable to the prevention of fungal infection.